Plain-English translation of NCT04104776 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called (DZR123) to see if it can help people with advanced cancers that have stopped responding to standard treatments. The study is divided into two parts: first, researchers will find the right dose by gradually increasing it in small groups of patients; then, they will test this dose in larger groups of people with specific cancer types, some of which have particular genetic mutations.
Many patients with advanced cancers run out of effective treatment options, especially when their tumors have specific genetic changes. This medication is designed to target cancer cells with these changes, and researchers want to find out if this new treatment can slow or stop cancer growth in people who have few other options.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth once daily in 28-day treatment cycles. In Phase 1, you may have frequent visits to monitor your safety as the dose is gradually increased. In Phase 2, you will be assigned to a group based on your cancer type and genetic profile, and you will visit the clinic regularly to have blood tests, imaging scans, and physical exams. The study includes long-term follow-up visits approximately every 3 months for the first 3 years, then every 6 months afterward, to monitor how you respond and watch for any long-term effects.
AI-generated summary from trial data · Sep 2, 2026 · Not medical advice
United States